Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Authors:
- Bertrand CoiffierBCBertrand Coiffier
- Barbara ProBPBarbara Pro
- H. Miles PrinceH. Miles Prince
- Francine FossFFFrancine Foss
- Lubomir SokolLSLubomir Sokol
- Matthew GreenwoodMGMatthew Greenwood
- Dolores CaballeroDCDolores Caballero
- Peter BorchmannPBPeter Borchmann
- Franck MorschhauserFMFranck Morschhauser
- Martin WilhelmMWMartin Wilhelm
- Lauren Pinter-BrownLPLauren Pinter-Brown
- Swaminathan PadmanabhanSPSwaminathan Padmanabhan
Top Cited Papers
- 20 February 2012
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (6) , 631-636
Abstract
Purpose: Romidepsin is a structurally unique, potent class 1 selective histone deacetylase inhibitor. The primary objective of this international, pivotal, single-arm, phase II trial was to confirm the efficacy of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Patients and Methods: Patients who were refractory to at least one prior systemic therapy or for whom at least one prior systemic therapy failed received romidepsin at 14 mg/m2 as a 4-hour intravenous infusion on days 1, 8, and 15 every 28 days. The primary end point was the rate of complete response/unconfirmed complete response (CR/CRu) as assessed by an independent review committee. Results: Of the 131 patients enrolled, 130 had histologically confirmed PTCL by central review. The median number of prior systemic therapies was two (range, one to eight). The objective response rate was 25% (33 of 130), including 15% (19 of 130) with CR/CRu. Patient characteristics, prior stem-cell transplantation, number or type of prior therapies, or response to last prior therapy did not have an impact on response rate. The median duration of response was 17 months, with the longest response ongoing at 34+ months. Of the 19 patients who achieved CR/CRu, 17 (89%) had not experienced disease progression at a median follow-up of 13.4 months. The most common grade ≥ 3 adverse events were thrombocytopenia (24%), neutropenia (20%), and infections (all types, 19%). Conclusion: Single-agent romidepsin induced complete and durable responses with manageable toxicity in patients with relapsed or refractory PTCL across all major PTCL subtypes, regardless of the number or type of prior therapies. Results led to US Food and Drug Administration approval of romidepsin in this indication.Keywords
This publication has 25 references indexed in Scilit:
- Peripheral T-cell lymphomaBlood, 2011
- Evolving therapy of peripheral T-cell lymphoma: 2010 and beyondTherapeutic Advances in Hematology, 2011
- Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL StudyJournal of Clinical Oncology, 2011
- Impact of Autologous and Allogeneic Stem Cell Transplantation in Peripheral T-Cell LymphomasAdvances in Hematology, 2010
- International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical OutcomesJournal of Clinical Oncology, 2008
- Management of peripheral T-cell non-Hodgkin's lymphomaCurrent Opinion in Oncology, 2007
- Peripheral T- cell lymphomas: diagnosis and managementHematology/Oncology Clinics of North America, 2003
- Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. ClassificationAnnals of Oncology, 1998
- Epidemiology of the non-Hodgkin’s lymphomas: Distributions of the major subtypes differ by geographic locationsAnnals of Oncology, 1998
- Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. ClassificationAnnals of Oncology, 1997